April 2004
Gut;Apr2004 Supplement 3, Vol. 53, pA81
Academic Journal
Combination treatment with pegylated interferon α plus ribavirin produces significantly higher sustained virological response than treatment with interferon alone in patients with chronic hepatitis C virus (HCV) infection. Duration of treatment should be based on HCV genotype. Patients with genotype 1 should be treated for 48 weeks. Patients with genotype 2 or 3 should be treated for 24 weeks. There is inadequate information on optimal regimens of treatment for patients with other genotypes, like genotype 4. The objective of this study is to assess the efficacy of pegylated interferon α-2a plus ribavirin for the treatment of patients with chronic hepatitis C genotype 4.


Related Articles

  • Pegylated Interferon and Ribavirin Promote Early Evolution of Nonstructural 5A Protein in Individuals with Hepatitis C Who Demonstrate a Response to Treatment. Jain, Mamta K.; He-Jun Yuan; Adams-Huet, Beverley; Reeck, Amanda; Shelton, Janel; Attar, Nahid; Song Zhang; Neumann, Avidan U.; Carney, David S.; Gale, Jr., Michael; William M. Lee // Journal of Infectious Diseases;9/15/2009, Vol. 200 Issue 6, p866 

    Background. Hepatitis C virus (HCV) quasispecies diversity is more likely to affect early viral decline during treatment of hepatitis C than is having human immunodeficiency virus (HIV) infection.We evaluated the influence of HCV therapy on changes in the nonstructural 5A (NS5A) protein....

  • Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in Hepatitis C virus replicon. Hazari, Sidhartha; Taylor, Lizeth; Haque, Salima; Garry, Robert F.; Florman, Sander; Luftig, Ronald; Regenstein, Frederic; Dash, Srikanta // Virology Journal;2007, Vol. 4, p89 

    Background: Alpha interferon in combination with ribavirin is the standard therapy for hepatitis C virus infection. Unfortunately, a significant number of patients fail to eradicate their infection with this regimen. The mechanisms of IFN-resistance are unclear. The aim of this study was to...

  • Pegylated Interferon-α-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial. Chen-Hua Liu; Chun-Jen Liu; Chih-Lin Lin; Cheng-Chao Liang; Shih-Jer Hsu; Sheng-Shun Yang; Ching-Sheng Hsu; Tai-Chung Tseng; Chia-Chi Wang; Ming-Yang Lai; Jun-Herng Chen; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao // Clinical Infectious Diseases;11/15/2008, Vol. 47 Issue 10, p1260 

    Background. Comparable sustained virologic response (SVR) rates have been documented between Asian patients who received 24 weeks of pegylated interferon (IFN) plus ribavirin and white patients who received 48 weeks of combination therapy for hepatitis C virus genotype 1 (HCV-1) infection....

  • Hepatitis C Treatment: Trial by Design. Bzeizi, Khalid I. // Saudi Journal of Gastroenterology;Apr-Jun2008, Vol. 14 Issue 2, p51 

    The author comments on the findings of a study about the treatment outcome of 335 hepatitis C virus (HCV) patients treated with peginterferon α-2a and ribavirin combination therapy in Saudi Arabia. He states that the divergence of the study's findings from the prospective studies published...

  • Hepatitis C Virus Envelope Glycoprotein Signatures Are Associated With Treatment Failure and Modulation of Viral Entry and Neutralization. Schvoerer, Evelyne; Moenne-Loccoz, Rémy; Murray, John M.; Velay, Aurélie; Turek, Marine; Fofana, Isabel; Fafi-Kremer, Samira; Erba, Anne-Claire; Habersetzer, François; Doffoël, Michel; Gut, Jean-Pierre; Donlin, Maureen J.; Tavis, John E.; Zeisel, Mirjam B.; Stoll-Keller, Françoise; Baumert, Thomas F. // Journal of Infectious Diseases;Apr2013, Vol. 207 Issue 8, p1306 

    Background. A major challenge for antiviral treatment of hepatitis C virus (HCV) infection is viral resistance, potentially resulting from the high variability of HCV envelope glycoproteins and subsequent selection of strains with enhanced infectivity and/or immune escape.Methods. We used a...

  • Genetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus Ribavirin. Cuevas, José Manuel; Torres-Puente, Manuela; Jiménez-Hernández, Nuria; Bracho, María Alma; García-Robles, Inmaculada; Wrobel, Boris; Carnicer, Fernando; del Olmo, Juan; Ortega, Enrique; Moya, Andrés; González-Candelas, Fernando // PLoS ONE;2008, Vol. 3 Issue 8, p1 

    We present an analysis of the selective forces acting on two hepatitis C virus genome regions previously postulated to be involved in the viral response to combined antiviral therapy. One includes the three hypervariable regions in the envelope E2 glycoprotein, and the other encompasses the PKR...

  • Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients. Donlin, Maureen J.; Cannon, Nathan A.; Aurora, Rajeev; Jia Li; Wahed, Abdus S.; Bisceglie, Adrian M. Di; Tavis, John E. // PLoS ONE;2010, Vol. 5 Issue 2, p1 

    Background: Hepatitis C virus (HCV) has six major genotypes, and patients infected with genotype 1 respond less well to interferon-based therapy than other genotypes. African American patients respond to interferon α-based therapy at about half the rate of Caucasian Americans. The effect of...

  • Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations? Alsiö, Åsa; Christensen, Peer Brehm; Färkkilä, Martti; Langeland, Nina; Buhl, Mads Rauning; Pedersen, Court; Mørch, Kristine; Haagmans, Bart L.; Westin, Johan; Hellstrand, Kristoffer; Norkrans, Gunnar; Lagging, Martin // Clinical Infectious Diseases;2/15/2010, Vol. 50 Issue 4, pe22 

    Twelve of 303 per-protocol patients were nonresponders in a 12-week versus 24-week treatment study of hepatitis C virus (HCV) genotype 2/3 infection. The nonresponders had significantly lower interferon concentrations, as well as significantly greater mean age, body mass index, and viral load....

  • Long term changes in liver histology following treatment of chronic hepatitis C virus. Shiffman, Mitchell L.; Sterling, Richard K.; Contos, Melissa; Hubbard, Sarah; Long, April; Luketic, Velimir A.; Stravitz, R. Todd; Fuchs, Michael; Sanyal, Arun J. // Annals of Hepatology: Official Journal of the Mexican Associatio;Jul/Aug2014, Vol. 13 Issue 4, p340 

    Background and aims. The histologic hallmarks of chronic HCV include inflammation and fibrosis. The impact of interferon therapy on liver histology was evaluated. Material and methods. The study population consisted of 348 patients with chronic HCV who underwent a baseline liver biopsy, received...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics